(BUSINESS WIRE)--Galderma (SWX:GALD) announces positive first results from a trial designed to explore the benefits of Restylane® Lyft™ or Contour™ in combination with Sculptra® in patients with medication-driven weight loss with associated facial volume loss.1 Initial three-month interim data from this first-of-its-kind trial suggest that this treatment combination effectively improved facial aesthetic appearance with high patient satisfaction.1 The results will be presented later today at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California.
Rates of medication-driven weight loss have increased rapidly in recent years and can be associated with facial alterations of variable magnitude.2-4 Patients can find that their skin is less radiant, drier or saggy, and can also observe changes in their facial structure and balance.3,4 Some even find that they appear older than their age.3,4 There are several reasons for these facial alterations including loss of fat, collagen, elastin and essential nutrients such as fatty acids.4
|
“We initiated this trial because we have the unique expertise, capability, and products needed to rapidly respond to the evolving needs of patients and healthcare professionals. It is encouraging to see these early results, which demonstrate the potential of our existing Injectable Aesthetics portfolio in addressing the effects of medication-driven weight loss on the skin, and we’re looking forward to presenting the nine-month data in due course.”
FLEMMING ØRNSKOV, M.D., MPH
|
|
Three-month interim data provide response to one of the most predominant aesthetic concerns of patients taking prescription weight loss medicines
In a phase IV clinical trial conducted in the U.S., Galderma investigated the efficacy, safety, and patient satisfaction of Restylane Lyft™ or Contour™ in combination with Sculptra for cheek augmentation and correction of contour deficiencies in patients with medication-driven weight loss with associated facial volume loss.1 Informed by insights gained from pivotal trials of Sculptra and the Restylane portfolio, the trial took place across two sites and used the SHAPE Up Holistic Individualized Treatment (HIT™) as a treatment methodology.1 HIT™ is an individualized treatment approach which enables injectors to leverage their expertise with the renowned Galderma Restylane portfolio to optimize aesthetic outcomes while prioritizing patient satisfaction.
Patients were treated with Sculptra and either Restylane Lyft™ or Contour™ for their first treatment, a second treatment of Sculptra with an optional touch-up of Restylane Lyft™ or Contour™ at Week 4, and an optional third treatment of Sculptra at Week 8.1 Follow-up visits took place at Week 20 for those who received the third Sculptra treatment and at Week 16 for those who did not, corresponding to three months after their final treatment.1
Results at three months demonstrated that the combination of Sculptra and Restylane Lyft™ or Contour™ effectively improved the facial aesthetic appearance of patients experiencing significant medication-driven weight loss with associated facial volume loss, further supporting the benefits of the SHAPE Up HIT™:1
Safety was in line with previous pivotal trial data for all products, with no treatment-related adverse events reports.1
|
“As medication-driven weight loss becomes more prolific around the world, so do the associated impacts of facial volume loss and other unwanted cosmetic effects like shadowing and hollowness. This innovative study is going to be invaluable in exploring how best to address these facial alterations, with results so far being very promising.”
MICHAEL SOMENEK, MD
|
|
Galderma’s broad portfolio addresses key patient and healthcare professional needs
Galderma is well-positioned to address these alterations, given its expertise and experience in dermatology, specialized range of injectable treatments and skincare products, and its patient-centric approach, developed in close collaboration with leading healthcare professionals. While Sculptra - the first proven regenerative biostimulator with a unique poly-L-lactic acid (PLLA-SCA™) formulation - can help to restore skin integrity, our portfolio of Restylane hyaluronic acid injectables can help refine areas of the face that may have been altered during the weight loss journey.1,5-9
A six-month extension is now ongoing to confirm the long-term effects, a full nine months after final Sculptra treatment, to further confirm the benefits of the combination approach.
About the study
This phase IV trial was a multi-center, open-label study to evaluate the synergistic effects of Restylane® Lyft™ or Contour™ in combination with Sculptra® for cheek augmentation and correction of contour deficiencies, in patients experiencing facial volume loss following treatment with one of four brands of glucagon-like peptide-1 (GLP-1) receptor agonists.1 Conducted in the U.S., the trial took place across two sites, and used the SHAPE Up Holistic Individualized Treatment (HIT™) as a treatment methodology, with patients treated with Sculptra and either Restylane Lyft™ or Contour™ for their first treatment, a second treatment of Sculptra with an optional touch-up of Restylane Lyft™ or Contour™ at Week 4, and an optional third treatment of Sculptra at Week 8.1 Follow-up visits took place at Week 20 for those who received the third Sculptra treatment and at Week 16 for those who did not.1 Skin quality findings were assessed in the Sculptra/Restylane Lyft™ regimen.1
About Galderma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.
References
View source version on businesswire.com: https://www.businesswire.com/news/home/20250113255472/en/
For further information:
Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50
Sébastien Cros
Corporate Communications Director
sebastien.cros@galderma.com
+41 79 529 59 85
Emil Ivanov
Head of Strategy, Investor Relations, and ESG
emil.ivanov@galderma.com
+41 21 642 78 12
Jessica Cohen
Investor Relations and Strategy Director
jessica.cohen@galderma.com
+41 21 642 76 43
